Winselow Tucker, Eli Lilly's new Loxo unit chief commercial officer

Eli Lil­ly plucks a new com­mer­cial chief from Bris­tol My­ers in man­age­ment shuf­fle as HR chief re­tires

Eli Lil­ly has found a new chief com­mer­cial of­fi­cer from among the ranks at Bris­tol My­ers Squibb, as it says farewell to its long­time head of hu­man re­sources Stephen Fry.

Stephen Fry

Fry an­nounced on Thurs­day his plans to re­tire af­ter more than 35 years with Lil­ly. He’ll va­cate his seat as SVP of hu­man re­sources and di­ver­si­ty at the end of the year, and cur­rent Loxo CCO Er­ic Dozi­er is slat­ed to take his place. As a re­sult, BMS’ Win­selow Tuck­er is join­ing the team as Loxo CCO at the end of the month.

Tuck­er is leav­ing his post as in­ter­con­ti­nen­tal SVP at BMS, a job he’s held for on­ly about eight months. Be­fore that, he was the SVP and gen­er­al man­ag­er of the hema­tol­ogy busi­ness, where, among oth­er ac­com­plish­ments, he was one of the lead­ers be­hind the phar­ma gi­ant’s $300 mil­lion com­mit­ment to com­bat racial dis­par­i­ties.

Er­ic Dozi­er

“What I’m re­al­ly ex­cit­ed about is that this is a tan­gi­ble view,” he told End­points News back in 2020, “that we’re not just look­ing ex­ter­nal­ly, we’re al­so look­ing in­ter­nal­ly as well to fig­ure out how can we sup­port the right eq­ui­ty across both our in­ter­nal or­ga­ni­za­tions and in the com­mu­ni­ties of pa­tients that we serve.”

Tuck­er has been vo­cal about ad­dress­ing racial dis­par­i­ties with­in health­care and was al­so in­volved in BMS’ Stand­ing in the Gaap pro­gram de­signed to close gaps in the di­ag­no­sis, care and sur­vival rates of African Amer­i­cans with mul­ti­ple myelo­ma.

“I grew up in New York City, a city of con­trasts. I saw this first-hand when it came to in­for­ma­tion, ed­u­ca­tion, and op­por­tu­ni­ties. That aware­ness shaped who I am to­day and how I see and un­der­stand the world. I know that ac­cess to health­care and med­i­cines can change some­one’s life,” he wrote in a LinkedIn post mark­ing his 100th day as BMS’ in­ter­con­ti­nen­tal SVP.

Tuck­er added that he was ready to tran­si­tion from “the ini­tial pe­ri­od of lis­ten­ing and learn­ing to lean in­to our goals with full force.”

Ja­cob van Naar­den

“Win­selow brings deep ex­per­tise in both on­col­o­gy and hema­tol­ogy that will sup­port the con­tin­ued growth of our ex­ist­ing com­mer­cial port­fo­lio and ef­forts to bring our pipeline of can­cer med­i­cines to pa­tients around the world,” Ja­cob Van Naar­den, SVP and CEO Lil­ly’s Loxo unit, said in a news re­lease.

Fry is head­ing in­to re­tire­ment af­ter more than 35 years at Eli Lil­ly, where he start­ed as a sys­tems an­a­lyst in In­di­ana back in 1987, ac­cord­ing to his LinkedIn pro­file. Fry’s po­si­tions have spanned the globe, in­clud­ing HR di­rec­tor in the UK and gen­er­al man­ag­er in Aus­tralia and New Zealand.

Dave Ricks

“Steve has left a pos­i­tive and in­deli­ble im­print on the peo­ple, cul­ture and per­for­mance of our com­pa­ny,” CEO David Ricks said in a news re­lease. “Serv­ing as our CHRO over the past 11 years, Steve has played a key role in lead­ing us through the chal­lenges we faced in those ear­ly years, mod­ern­iz­ing so many di­men­sions of our HR func­tion—in­clud­ing di­ver­si­ty, eq­ui­ty and in­clu­sion—and lead­ing the com­pa­ny’s ef­forts to be­come a pre­mier em­ploy­er around the world.”

That leaves Dozi­er with some big shoes to fill, though Ricks is con­fi­dent he’s up for the task. Dozi­er has been with Lil­ly for near­ly 25 years, hop­ping from roles such as chief mar­ket­ing of­fi­cer for Japan to VP of glob­al ethics and com­pli­ance be­fore set­tling in as Loxo CCO.

“Er­ic is the right leader to dri­ve our peo­ple strat­e­gy and di­ver­si­ty, eq­ui­ty, and in­clu­sion agen­da as Lil­ly en­ters a new and ex­cit­ing chap­ter of growth,” Ricks said.

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

APAC is the fastest growing region globally for cell & gene therapy trials representing more than a third of all cell & gene studies globally, with China leading in the region. 

APAC is the leading location globally for CAR-T trials with China attracting ~60% of all CAR-T trials globally between 2015-2022. The number of CAR-T trials initiated by Western companies has rapidly increased in recent years (current CAGR of about 60%), with multiple targets being explored including CD19, CD20, CD22, BCMA, CD30, CD123, CD33, CD38, and CD138.

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

Reading about John Carroll’s pick of biotech’s most promising startups has become a treasured tradition. If you ever get curious about previous classes of the Endpoints 11, you can find all of them (plus a number of our other regular specials) here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

The EMA is putting EU member states on alert over the shortage of two drugs that counter heart attacks due to an uptick in demand.

On Friday, the EMA sent out a warning that two Boehringer Ingelheim drugs are experiencing a shortage: Actilyse and Metalyse. The drugs are used as emergency treatments for adults experiencing acute myocardial infarction, or a heart attack, by dissolving blood clots that have formed in the blood vessels.

The End­points 11: The top pri­vate biotechs in pur­suit of new drugs. Push­ing the en­ve­lope with pow­er­ful new tech­nolo­gies

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.

In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made a comeback, with more burned out shells to go public at a time IPOs and road shows are out of favor. And no doubt some of the more recent arrivals on the investing side of the business are finding greener pastures.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Wendy Lund, WPP chief client officer for health and wellness

WPP taps Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund for new health and well­ness client role

Wendy Lund is going home – to WPP, that is. Lund is leaving the Merck women’s health spinoff Organon where she is chief communications officer for a newly created role as WPP chief client officer for health and wellness. Before Organon, Lund led GCI Group, a WPP healthcare communications agency, as CEO for 11 years.

Lund joins WPP’s group of global client leaders who act as a single point of contact or entry for clients with WPP brands and businesses inside the holding company. and in this case, for the WPP health and wellness business.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

Solicitor General Elizabeth Prelogar

Should SCO­TUS hear Am­gen's Repatha case? So­lic­i­tor gen­er­al says no

Back in April, Amgen said it was encouraged by the solicitor general’s anticipated review of its Supreme Court petition to rehear a Repatha patent case. They’re likely much less optimistic about the outcome now.

Solicitor General Elizabeth Prelogar wrote in a recent 27-page brief that Amgen’s arguments “lack merit and further review is not warranted.”

The case traces back to a suit filed in 2014 against Sanofi and Regeneron’s Praluent, which ended up beating Amgen’s PCSK9 blockbuster Repatha to market by a month just a year later.

Klick Health gath­ers biotech and phar­ma lu­mi­nar­ies to dis­cuss in­dus­try in­no­va­tions, in­vest­ments and fu­ture

At Klick Health’s first Ideas Exchange conference with biotech and pharma industry insiders since before the pandemic began, it was no surprise many conversations included Covid topics. Yet while vaccines and treatments were discussed, so too were the effects on drug development, federal responses, health inequities — and what to do now and next.

George Yancopoulos, chief scientist and cofounder of Regeneron, opened the conference responding to a question from Acorda CEO Ron Cohen about the spotlight on the industry during Covid and some of the “flak” biopharma has taken in the past.

FDA's out­side ex­perts vote in fa­vor of Fer­ring's fe­cal trans­plant for C. dif­fi­cile, set­ting the stage for Seres

FDA’s outside advisors voted in favor of Ferring Pharmaceuticals’ RBX2660, an experimental poop-based drug implant that the company says would be the first microbiota-based live biotherapeutic to receive an FDA green light.

That was a point repeatedly discussed during the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, meeting Thursday when evaluating Ferring’s fecal microbiota transplant, or FMT, for reducing the recurrence of Clostridioides difficile infection in adults who have received antibiotics. Multiple members brought up the need for a regulated product amid a landscape of unregulated FMTs already happening in clinical care.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis un­veils 'US-first' strat­e­gy ahead of San­doz spin­off

Weeks after announcing the spinoff of generics arm Sandoz, Vas Narasimhan paints a picture of the new, slimmer Novartis — with a “US-first mindset,” he said at an investor event on Thursday.

The CEO unveiled ambitious plans to become a top-five player in the US by 2027 at Novartis’ “Meet the Management” event in Basel, Switzerland, which means ramping up clinical trials in the states and “building capability and talent, among other things.” The company’s also shooting for a top-three ranking in China.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.